PL405076A1 - Zastosowanie alpha-cyklodrkstryny do wytwarzania leku do obnizenia poziomów leptyny, poziomów insuliny lub opornosci na insuline - Google Patents

Zastosowanie alpha-cyklodrkstryny do wytwarzania leku do obnizenia poziomów leptyny, poziomów insuliny lub opornosci na insuline

Info

Publication number
PL405076A1
PL405076A1 PL405076A PL40507603A PL405076A1 PL 405076 A1 PL405076 A1 PL 405076A1 PL 405076 A PL405076 A PL 405076A PL 40507603 A PL40507603 A PL 40507603A PL 405076 A1 PL405076 A1 PL 405076A1
Authority
PL
Poland
Prior art keywords
levels
insulin
cyclodextrin
medicament
manufacture
Prior art date
Application number
PL405076A
Other languages
English (en)
Other versions
PL220779B1 (pl
Inventor
Catherine Jen
Joseph D. Artiss
Original Assignee
Soho Flordis International Pty Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soho Flordis International Pty Ltd. filed Critical Soho Flordis International Pty Ltd.
Publication of PL405076A1 publication Critical patent/PL405076A1/pl
Publication of PL220779B1 publication Critical patent/PL220779B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D13/00—Finished or partly finished bakery products
    • A21D13/80—Pastry not otherwise provided for elsewhere, e.g. cakes, biscuits or cookies
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/14—Organic oxygen compounds
    • A21D2/18—Carbohydrates
    • A21D2/181—Sugars or sugar alcohols
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/14—Organic oxygen compounds
    • A21D2/18—Carbohydrates
    • A21D2/186—Starches; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L15/00—Egg products; Preparation or treatment thereof
    • A23L15/30—Addition of substances other than those covered by A23L15/20 – A23L15/25
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
    • A23L25/10—Peanut butter
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/88—Taste or flavour enhancing agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A23L29/35—Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
    • A23L5/27—Removal of unwanted matter, e.g. deodorisation or detoxification by chemical treatment, by adsorption or by absorption
    • A23L5/273—Removal of unwanted matter, e.g. deodorisation or detoxification by chemical treatment, by adsorption or by absorption using adsorption or absorption agents, resins, synthetic polymers, or ion exchangers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/109—Types of pasta, e.g. macaroni or noodles
    • A23L7/111—Semi-moist pasta, i.e. containing about 20% of moist; Moist packaged or frozen pasta; Pasta fried or pre-fried in a non-aqueous frying medium, e.g. oil; Packaged pasta to be cooked directly in the package
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/117—Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
    • A23L7/126—Snacks or the like obtained by binding, shaping or compacting together cereal grains or cereal pieces, e.g. cereal bars
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L9/00—Puddings; Cream substitutes; Preparation or treatment thereof
    • A23L9/10—Puddings; Dry powder puddings
    • A23L9/12—Ready-to-eat liquid or semi-liquid desserts, e.g. puddings, not to be mixed with liquids, e.g. water, milk
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P30/00—Shaping or working of foodstuffs characterised by the process or apparatus
    • A23P30/40—Foaming or whipping
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Edible Oils And Fats (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Fodder In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Wynalazek dotyczy zastosowania ?-cyklodekstryny do wytwarzania leku do obnizania poziomów leptyny, poziomów insuliny lub opornosci na insuline, w którym wymagajacemu tego podmiotowi podaje sie wystarczajaca ilosc leku do obnizenia poziomów leptyny, poziomów insuliny lub opornosci na insuline, przy czym stosunek ilosci podawanej ?-cyklodekstryny i ilosci tluszczu spozywanego dziennie przez wymieniony podmiot wynosi od 1:20 do 1:3 wagowo.
PL405076A 2002-08-19 2003-07-29 Zastosowanie α-cyklodekstryny do wytwarzania leku do obniżania poziomów leptyny, poziomów insuliny lub oporności na insulinę PL220779B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40436602P 2002-08-19 2002-08-19
US46184703P 2003-04-11 2003-04-11
US48644003P 2003-07-14 2003-07-14

Publications (2)

Publication Number Publication Date
PL405076A1 true PL405076A1 (pl) 2013-12-09
PL220779B1 PL220779B1 (pl) 2016-01-29

Family

ID=31892100

Family Applications (6)

Application Number Title Priority Date Filing Date
PL405076A PL220779B1 (pl) 2002-08-19 2003-07-29 Zastosowanie α-cyklodekstryny do wytwarzania leku do obniżania poziomów leptyny, poziomów insuliny lub oporności na insulinę
PL405077A PL220776B1 (pl) 2002-08-19 2003-07-29 Zastosowanie α-cyklodekstryny do wytwarzania leku do zmniejszania biegunki
PL396944A PL220645B1 (pl) 2002-08-19 2003-07-29 Zastosowanie α-cyklodekstryny do wytwarzania leku do ułatwiania utraty masy ciała
PL405074A PL220643B1 (pl) 2002-08-19 2003-07-29 Zastosowanie α-cyklodekstryny do wytwarzania leku do obniżania poziomów trójglicerydów
PL375374A PL213863B1 (pl) 2002-08-19 2003-07-29 Konsumpcyjny maczny produkt zywnosciowy, konsumpcyjny niemaczny produkt zywnosciowy, sposób polepszania organoleptycznych wlasciwosci zawierajacego tluszcz konsumpcyjnego produktu zywnosciowego i sposób zmniejszania dostepnosci biologicznej tluszczu w konsumpcyjnym zawierajacym tluszcz produkcie zywnosciowym
PL405075A PL220780B1 (pl) 2002-08-19 2003-07-29 Zastosowanie α-cyklodekstryny do wytwarzania leku do podwyższania poziomu cholesterolu lipoproteinowego o wysokiej gęstości (HDL) oraz do zmniejszania stosunku cholesterol/HDL

Family Applications After (5)

Application Number Title Priority Date Filing Date
PL405077A PL220776B1 (pl) 2002-08-19 2003-07-29 Zastosowanie α-cyklodekstryny do wytwarzania leku do zmniejszania biegunki
PL396944A PL220645B1 (pl) 2002-08-19 2003-07-29 Zastosowanie α-cyklodekstryny do wytwarzania leku do ułatwiania utraty masy ciała
PL405074A PL220643B1 (pl) 2002-08-19 2003-07-29 Zastosowanie α-cyklodekstryny do wytwarzania leku do obniżania poziomów trójglicerydów
PL375374A PL213863B1 (pl) 2002-08-19 2003-07-29 Konsumpcyjny maczny produkt zywnosciowy, konsumpcyjny niemaczny produkt zywnosciowy, sposób polepszania organoleptycznych wlasciwosci zawierajacego tluszcz konsumpcyjnego produktu zywnosciowego i sposób zmniejszania dostepnosci biologicznej tluszczu w konsumpcyjnym zawierajacym tluszcz produkcie zywnosciowym
PL405075A PL220780B1 (pl) 2002-08-19 2003-07-29 Zastosowanie α-cyklodekstryny do wytwarzania leku do podwyższania poziomu cholesterolu lipoproteinowego o wysokiej gęstości (HDL) oraz do zmniejszania stosunku cholesterol/HDL

Country Status (22)

Country Link
US (4) US6890549B2 (pl)
EP (4) EP1478401B1 (pl)
JP (3) JP4418751B2 (pl)
CN (1) CN100542609C (pl)
AT (1) ATE442165T1 (pl)
AU (1) AU2003259235B2 (pl)
BR (1) BRPI0309572B1 (pl)
CA (2) CA2480668C (pl)
CY (1) CY1115026T1 (pl)
DE (1) DE60329168D1 (pl)
DK (2) DK2138190T3 (pl)
ES (1) ES2457017T3 (pl)
IL (2) IL164332A0 (pl)
MA (1) MA27959A1 (pl)
MX (1) MXPA04012880A (pl)
NO (2) NO334081B1 (pl)
NZ (1) NZ535665A (pl)
PL (6) PL220779B1 (pl)
PT (1) PT2138190E (pl)
SI (1) SI2138190T1 (pl)
WO (1) WO2004016101A2 (pl)
ZA (1) ZA200407806B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1478401B1 (en) * 2002-08-19 2009-09-09 Art Jen Complexus Inc. Compositions comprising dietary fat complexer and methods for their use
US20040116382A1 (en) * 2002-12-13 2004-06-17 Plank David W. Food products containing cyclodextrins having beneficial hypocholesterolemic effects and method of making and communicating the benefit of such products
EP1447013A1 (en) * 2003-02-14 2004-08-18 Wacker-Chemie GmbH Method for reducing the glycemic index of food
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
US7335386B2 (en) 2003-07-30 2008-02-26 Gerneral Mills, Inc. Method for preventing acrylamide formation in food products and food intermediates
US20040180125A1 (en) * 2003-03-11 2004-09-16 Plank David W. Cyclodextrin-containing compositions and methods
CA2547934C (en) * 2004-02-19 2013-05-21 Abbott Laboratories Methods of using gamma cyclodextrin to control blood glucose and insulin secretion
US7780873B2 (en) * 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
US7736684B2 (en) * 2004-06-22 2010-06-15 General Mills, Inc. Viscous fat compositions having low amounts of trans-fat, methods and products
US20070003681A1 (en) * 2005-06-30 2007-01-04 Kraft Foods Holdings, Inc. Stable aerated food products containing oil and cyclodextrin
AU2006335082B2 (en) * 2005-12-22 2011-09-29 General Mills, Inc. Method of making complexed fat compositions
WO2007073543A2 (en) * 2005-12-22 2007-06-28 General Mills, Inc. Method of preferentially reducing absorption of saturated fat and compositions
JP2008031055A (ja) * 2006-06-29 2008-02-14 Shunkosha:Kk 酢酸を含有してなる摂取用組成物
US20090023682A1 (en) * 2007-07-19 2009-01-22 Joseph Artiss Composition Comprising Dietary Fat Complexer and Methods of Using Same
US20100112122A1 (en) * 2008-04-30 2010-05-06 Yun-Jeong Hong Method of preferentially reducing absorbability of saturated fatty acids
MY183041A (en) 2008-05-13 2021-02-08 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- {[1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
AU2011228758A1 (en) 2010-03-13 2012-11-08 Eastpond Laboratories Limited Fat-binding compositions
EP2568827B1 (en) * 2010-05-14 2018-04-25 Omega Pharma Innovation & Development NV Composition for reducing absorption of dietary fat
US10052345B2 (en) 2010-10-19 2018-08-21 University Of Miami Assays, methods and kits for predicting renal disease and personalized treatment strategies
CA2822995C (en) 2010-12-31 2021-05-11 Eastpond Laboratories Limited Cellular hydration compositions containing cyclodextrins
US20120171184A1 (en) 2010-12-31 2012-07-05 Lajos Szente Cellular hydration compositions
CN111419870A (zh) * 2012-04-13 2020-07-17 L&F研究有限公司 使用环糊精的方法
US9636048B2 (en) 2013-03-14 2017-05-02 Group Mee Llc Specialized sensors and techniques for monitoring personal activity
JP6735964B2 (ja) * 2016-04-28 2020-08-05 株式会社ハートテック 血糖値上昇抑制の加工食品
EP3687549A4 (en) 2017-09-28 2021-07-14 Asdera LLC USE OF CYCLODEXTRIN IN DISEASES AND DISORDERS WITH PHOSPHOLIPID FAILURE REGULATION
JP7120068B2 (ja) * 2018-02-28 2022-08-17 トヨタ紡織株式会社 動物の育成方法及び育成装置
US11660283B2 (en) 2018-12-19 2023-05-30 Joyn Botanicals Ltd. Cannabinoid-containing composition
JP2023520903A (ja) 2020-04-06 2023-05-22 イーストポンド・ラボラトリーズ・リミテッド 細胞水和を促進するための組成物
CN115104733A (zh) * 2021-03-18 2022-09-27 南京壹盛康品生物科技有限公司 α-环糊精在制备降脂食品、保健品及药物中的应用
CN115105524A (zh) * 2021-03-18 2022-09-27 南京壹盛康品生物科技有限公司 α-环糊精在制备改善和保护胰岛功能方面的功能食品或保健品及药物中的应用
CN116349747A (zh) * 2021-12-28 2023-06-30 南京盛德生物科技研究院有限公司 一种能自发泡的健康液体脂肪组合物及其制备方法与应用
CN115067393B (zh) * 2022-05-31 2024-04-12 古茗科技集团有限公司 打发辅助剂、其的制备方法、应用及奶盖打发方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5210448A (en) 1975-07-15 1977-01-26 Teijin Ltd Method of producing processed oil and fat food
JPS6049752A (ja) 1983-08-29 1985-03-19 Sanyuu Shoji Kk 栄養食品組成物
JPS6094912A (ja) 1983-10-28 1985-05-28 Masashige Suzuki 体内中性脂肪低減剤
JPS60149752A (ja) 1984-01-11 1985-08-07 Furukawa Electric Co Ltd:The 高力アルミニウム合金導体の製造方法
JPS60219720A (ja) 1984-04-16 1985-11-02 株式会社村田製作所 電気二重層コンデンサとその製造方法
JPS6211072A (ja) * 1985-07-08 1987-01-20 Kokusai:Kk 痩身用食品
FR2601959B1 (fr) * 1986-07-24 1988-12-02 Monserbio Gie Procede d'elimination du cholesterol contenu dans une matiere grasse d'origine animale et matiere grasse appauvrie en cholesterol obtenue
US5232725A (en) * 1989-03-14 1993-08-03 S.A.N. Corman Process for reducing the content of cholesterol and of free fatty acids in an animal fat
JPH0722483B2 (ja) 1989-03-31 1995-03-15 鐘淵化学工業株式会社 ケーキ用水中油型油脂組成物及びそれを利用したケーキ類の製造法
US5264241A (en) * 1989-06-29 1993-11-23 Roquette Freres Process for manufacturing dairy products with a reduced sterol content
US5264226A (en) * 1989-07-12 1993-11-23 Roquette Freres Process for preparing dairy products with a low content of sterols, particularly of cholesterol
JPH07115934B2 (ja) 1989-10-12 1995-12-13 日本特殊陶業株式会社 β―サイアロン焼結体
US5198250A (en) * 1990-07-16 1993-03-30 Lipotech Partners Limited Partnership Food and pharmaceutical compositions containing short chain monounsaturated fatty acids and methods of using
IT1243192B (it) 1990-08-09 1994-05-24 Staroil Ltd Complessi di acidi grassi polinsaturi a lunga catena e di loro derivati, con ciclodestrine
ES2033193B1 (es) * 1990-10-30 1994-01-16 Ganadera Union Ind Agro Mezcla grasa para nutricion infantil y de adultos.
JPH04237477A (ja) * 1991-01-22 1992-08-25 Ezaki Glico Co Ltd メレンゲの製造法
JPH04333575A (ja) 1991-01-29 1992-11-20 Nippon Parkerizing Co Ltd チタン含有金属材料上に複合被覆膜層を形成する方法
JP2646160B2 (ja) * 1991-03-08 1997-08-25 美穂 田中 愛玩鳥類用飼料とその製造法
JPH06511270A (ja) * 1991-09-06 1994-12-15 コモンウェルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼイション コレステロール濃度を低下させる組成物および方法
JPH05113603A (ja) 1991-10-23 1993-05-07 Tohoku Ricoh Co Ltd オーバーヘツドプロジエクタ装置
US5254541A (en) * 1991-11-15 1993-10-19 Merck Frosst Canada, Inc. (Quinolin-2-ylmethoxy)indole/cyclodextrin complex
JP2559311B2 (ja) 1991-12-12 1996-12-04 本田技研工業株式会社 多連スロットルボディの燃料配管構造
US5215922A (en) * 1992-02-05 1993-06-01 The Board Of Governors Of Wayne State University Method and compositions for the determination of serum calcium using aersenazo III
JPH05298849A (ja) 1992-04-16 1993-11-12 Sony Corp 浮上型磁気ヘッド装置
JPH05298850A (ja) 1992-04-22 1993-11-12 Hitachi Ltd 磁気記録装置およびそのスライダ
JPH07102113B2 (ja) 1992-11-18 1995-11-08 日成興産株式会社 痩身用食品
JPH0813257B2 (ja) * 1992-11-25 1996-02-14 日成興産株式会社 痩身用食品
JP3230884B2 (ja) * 1993-03-18 2001-11-19 日清製油株式会社 冷凍解凍耐性のあるクリーム状組成物及びその製造方法
JP2605208B2 (ja) 1993-04-15 1997-04-30 逸郎 松島 痩身用食品
JP2510943B2 (ja) 1993-06-07 1996-06-26 株式会社ドクターマインツ 痩身用食品
DE4331565A1 (de) 1993-09-16 1995-03-23 Consortium Elektrochem Ind Verfahren zur Reduktion des Gehalts an Triglyceriden im Eigelb und in eigelbhaltigen Produkten
JPH07115935A (ja) 1993-10-22 1995-05-09 Hairu:Kk 痩身用食品
JPH07115934A (ja) 1993-10-22 1995-05-09 Hairu:Kk 痩身用食品
US5894029A (en) * 1994-03-21 1999-04-13 Purebred Pet Products, Inc. Method of making pet snack food
EP0733061A1 (en) * 1994-11-12 1996-09-25 LG Chemical Limited Cholesteryl ester transfer protein inhibitor peptides and prophylactic and therapeutic anti-arteriosclerosis agents
KR100247233B1 (ko) * 1995-02-22 2000-06-01 마이클 엘. 퓨어링 동물지방에서 스테롤과 유리지방산의 감소방법
JP3375780B2 (ja) 1995-03-29 2003-02-10 三井化学株式会社 重包装袋用ポリエチレン樹脂組成物およびその組成物からなる重包装袋用ポリエチレン樹脂フィルム
US5738898A (en) 1995-03-31 1998-04-14 Board Of Trustees Operating Michigan State University Process for reducing sterols in eggs
US5560950A (en) * 1995-05-31 1996-10-01 Campbell Soup Company Free fatty acid removal from used frying fat
US5532009A (en) * 1995-06-07 1996-07-02 The Procter & Gamble Company Fat substitutes containing water soluble beta-carotene
JP2934658B2 (ja) * 1995-12-25 1999-08-16 美穂 田中 クロレラエキス粉末の製造法
IL117773A (en) * 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
US5965449A (en) * 1996-07-03 1999-10-12 Forbes Medi-Tech, Inc. Method of assessing risk for cardiovascular disease and other disorders and phytosterol-based compositions useful in preventing and treating cardiovascular disease and other disorders
JP2000116337A (ja) 1998-10-09 2000-04-25 Nippon Shokuhin Kako Co Ltd ペットフード
US6129945A (en) * 1998-12-10 2000-10-10 Michael E. George Methods to reduce free fatty acids and cholesterol in anhydrous animal fat
JP2002306119A (ja) * 2001-04-17 2002-10-22 Toyo Olive Co Ltd 健康維持機能に優れたオリーブマヨネーズの製造法
US20030190402A1 (en) 2002-04-04 2003-10-09 Mcbride Christine Reduced fat foodstuff with improved flavor
US20030232068A1 (en) * 2002-06-14 2003-12-18 Lewandowski Daniel J. Food product having increased bile acid binding capacity
EP1478401B1 (en) * 2002-08-19 2009-09-09 Art Jen Complexus Inc. Compositions comprising dietary fat complexer and methods for their use
US20040116382A1 (en) * 2002-12-13 2004-06-17 Plank David W. Food products containing cyclodextrins having beneficial hypocholesterolemic effects and method of making and communicating the benefit of such products
JP5113603B2 (ja) 2008-04-18 2013-01-09 日立建機株式会社 電動式作業機械
JP5164024B2 (ja) 2008-09-16 2013-03-13 Ｔｄｋ株式会社 積層セラミック電子部品の製造方法

Also Published As

Publication number Publication date
PL405077A1 (pl) 2013-12-09
PL396944A1 (pl) 2012-03-26
PL220780B1 (pl) 2016-01-29
WO2004016101A3 (en) 2004-04-29
CA2677430C (en) 2014-02-18
MA27959A1 (fr) 2006-07-03
SI2138190T1 (sl) 2014-05-30
DK2138190T3 (da) 2014-05-12
EP2623120A3 (en) 2013-11-13
EP2138190A3 (en) 2010-05-12
HK1140407A1 (en) 2010-10-15
DK1478401T3 (da) 2010-01-18
PL220776B1 (pl) 2016-01-29
ZA200407806B (en) 2005-12-28
US20040120984A1 (en) 2004-06-24
ES2457017T3 (es) 2014-04-24
EP1478401A4 (en) 2007-10-24
PL220643B1 (pl) 2015-11-30
PL220645B1 (pl) 2015-11-30
US6890549B2 (en) 2005-05-10
BR0309572A (pt) 2005-02-09
WO2004016101A2 (en) 2004-02-26
PL213863B1 (pl) 2013-05-31
JP2009298820A (ja) 2009-12-24
HK1072184A1 (en) 2005-08-19
PT2138190E (pt) 2014-04-14
EP2623120B1 (en) 2020-04-01
JP2005536205A (ja) 2005-12-02
EP2623120A2 (en) 2013-08-07
JP5865296B2 (ja) 2016-02-17
DE60329168D1 (de) 2009-10-22
US20050019375A1 (en) 2005-01-27
PL220779B1 (pl) 2016-01-29
EP2641615A3 (en) 2014-01-08
BRPI0309572B1 (pt) 2017-02-21
EP2138190B1 (en) 2014-02-12
CA2480668A1 (en) 2004-02-26
CA2677430A1 (en) 2004-02-26
EP1478401A2 (en) 2004-11-24
US9326539B2 (en) 2016-05-03
JP5448683B2 (ja) 2014-03-19
EP2641615A2 (en) 2013-09-25
PL375374A1 (pl) 2005-11-28
AU2003259235B2 (en) 2007-08-23
NO20130555L (no) 2004-11-24
NO334081B1 (no) 2013-12-09
US20120309712A1 (en) 2012-12-06
MXPA04012880A (es) 2005-07-05
CN1662258A (zh) 2005-08-31
PL405075A1 (pl) 2013-12-09
US8586076B2 (en) 2013-11-19
CN100542609C (zh) 2009-09-23
PL405074A1 (pl) 2013-12-09
EP2138190A2 (en) 2009-12-30
US8101201B2 (en) 2012-01-24
IL164332A (en) 2010-11-30
NZ535665A (en) 2008-03-28
AU2003259235A1 (en) 2004-03-03
US20140107067A1 (en) 2014-04-17
JP4418751B2 (ja) 2010-02-24
NO339166B1 (no) 2016-11-14
CA2480668C (en) 2009-11-24
JP2013177448A (ja) 2013-09-09
CY1115026T1 (el) 2016-12-14
IL164332A0 (en) 2005-12-18
EP1478401B1 (en) 2009-09-09
ATE442165T1 (de) 2009-09-15
NO20044516L (no) 2004-11-24

Similar Documents

Publication Publication Date Title
PL405076A1 (pl) Zastosowanie alpha-cyklodrkstryny do wytwarzania leku do obnizenia poziomów leptyny, poziomów insuliny lub opornosci na insuline
NO20071505L (no) Fremgangsmate for sammensetting av legemiddelavgivelsesanordninger.
TW200718418A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
BRPI0519803A2 (pt) métodos para purificar trans-(-)-delta9-tetraidrocanabinol e trans-(+)-delta9-tetraidrocanabinol
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
MX2009011358A (es) Derivados de pirimidinona y metodos para su uso.
WO2007028058A3 (en) Adjustable stiffness catheter
DK1576970T3 (da) Intraluminal indretning med en coating, der indeholder et terapeutisk middel
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
SE0300010D0 (sv) Novel Compounds
MY137053A (en) Pyrimidine derivatives and their use as cb2 modulators
GB0222495D0 (en) Compounds
ATE441333T1 (de) Zusammensetzung enthaltend oligosaccharide als lísliche ballaststoffe zur verwendung gegen muskelschwund
WO2007002572A3 (en) Nattokinase for reducing whole blood viscosity
MXPA05002930A (es) Composiciones para la inhibicion de la proteina cinasa c alfa para el tratamiento de diabetes mellitus y enfermedades cardiovasculares.
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
TNSN07263A1 (en) Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
MX2007003157A (es) 4-feniltetrahidroisoquinolinas sustituidas, metodo para su produccion, su uso como medicamento y un medicamento que las contiene.
MY139498A (en) Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines
GEP20084490B (en) Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses thereof
WO2008058358A3 (en) Descriptive report of the patent of invention of the medicament 'rosuvastatin + metformin' in combined form for cardiovascular diseases.
TW200633696A (en) Sesamin/episesamin compositions
SE0102147D0 (sv) New methods